drugset / Trial / NCT00149981

A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

NCT00149981 ↗

Expanded access No longer available Novartis Pharmaceuticals

Summary

Facilitated access to everolimus until it is commercially available and reimbursable by appropriate parties

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule — —